Literature DB >> 25186605

Peptides and peptidomimetics as immunomodulators.

Ameya S Gokhale1, Seetharama Satyanarayanajois.   

Abstract

Peptides and peptidomimetics can function as immunomodulating agents by either blocking the immune response or stimulating the immune response to generate tolerance. Knowledge of B- or T-cell epitopes along with conformational constraints is important in the design of peptide-based immunomodulating agents. Work on the conformational aspects of peptides, synthesis and modified amino acid side chains have contributed to the development of a new generation of therapeutic agents for autoimmune diseases and cancer. The design of peptides/peptidomimetics for immunomodulation in autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, systemic lupus and HIV infection is reviewed. In cancer therapy, peptide epitopes are used in such a way that the body is trained to recognize and fight the cancer cells locally as well as systemically.

Entities:  

Keywords:  T-cell epitope; cyclotide; immunomodulation; peptide-based vaccine; peptidomimetics; β-amino acid

Mesh:

Substances:

Year:  2014        PMID: 25186605      PMCID: PMC4201125          DOI: 10.2217/imt.14.37

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  137 in total

Review 1.  More than one reason to rethink the use of peptides in vaccine design.

Authors:  Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

Review 2.  Peptidomimetics, a synthetic tool of drug discovery.

Authors:  Josef Vagner; Hongchang Qu; Victor J Hruby
Journal:  Curr Opin Chem Biol       Date:  2008-05-14       Impact factor: 8.822

3.  T cell determinants incorporating beta-amino acid residues are protease resistant and remain immunogenic in vivo.

Authors:  Andrew I Webb; Michelle A Dunstone; Nicholas A Williamson; Jason D Price; Andrea de Kauwe; Weisan Chen; Aaron Oakley; Patrick Perlmutter; James McCluskey; Marie-Isabel Aguilar; Jamie Rossjohn; Anthony W Purcell
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

4.  Molecular dissection of the CD2-CD58 counter-receptor interface identifies CD2 Tyr86 and CD58 Lys34 residues as the functional "hot spot".

Authors:  M Kim; Z Y Sun; O Byron; G Campbell; G Wagner; J Wang; E L Reinherz
Journal:  J Mol Biol       Date:  2001-09-28       Impact factor: 5.469

5.  Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.

Authors:  Daniele Vicari; Kevin C Foy; Eric M Liotta; Pravin T P Kaumaya
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

Review 6.  Cancer vaccines: preclinical studies and novel strategies.

Authors:  Claudia Palena; Scott I Abrams; Jeffrey Schlom; James W Hodge
Journal:  Adv Cancer Res       Date:  2006       Impact factor: 6.242

7.  A general preparation of protected phosphoamino acids.

Authors:  Daniel E Petrillo; Dale R Mowrey; Shawn P Allwein; Roger P Bakale
Journal:  Org Lett       Date:  2012-02-22       Impact factor: 6.005

Review 8.  Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.

Authors:  Ramon Arens; Thorbald van Hall; Sjoerd H van der Burg; Ferry Ossendorp; Cornelis J M Melief
Journal:  Semin Immunol       Date:  2013-05-21       Impact factor: 11.130

9.  Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20.

Authors:  Russell N Johnson; Pavla Kopecková; Jindrich Kopecek
Journal:  Bioconjug Chem       Date:  2009-01       Impact factor: 4.774

Review 10.  Ace revisited: a new target for structure-based drug design.

Authors:  K Ravi Acharya; Edward D Sturrock; James F Riordan; Mario R W Ehlers
Journal:  Nat Rev Drug Discov       Date:  2003-11       Impact factor: 84.694

View more
  18 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Biologically Synthesized Peptides Show Remarkable Inhibition Activity against Angiotensin-Converting Enzyme: A Promising Approach for Peptide Development against Autoimmune Diseases.

Authors:  Nosheen Mujtaba; Nazish Jahan; Adil Jamal; Shazia Abrar; Shumaila Kiran; Atizaz Rasool; Md Belal Hossain; Fayez Saeed Bahwerth; Ibtesam Nomani; Khalid Javed Iqbal
Journal:  Biomed Res Int       Date:  2022-06-20       Impact factor: 3.246

3.  Predicting the Success of Fmoc-Based Peptide Synthesis.

Authors:  Ilanit Gutman; Ron Gutman; John Sidney; Leila Chihab; Michele Mishto; Juliane Liepe; Anthony Chiem; Jason Greenbaum; Zhen Yan; Alessandro Sette; Zeynep Koşaloğlu-Yalçın; Bjoern Peters
Journal:  ACS Omega       Date:  2022-06-27

Review 4.  Challenges in delivering therapeutic peptides and proteins: A silk-based solution.

Authors:  Junqi Wu; Jugal Kishore Sahoo; Yamin Li; Qiaobing Xu; David L Kaplan
Journal:  J Control Release       Date:  2022-02-11       Impact factor: 11.467

Review 5.  Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design.

Authors:  Sitanshu S Singh; Seetharama D Jois
Journal:  Adv Protein Chem Struct Biol       Date:  2017-10-06       Impact factor: 3.507

6.  Post-nano strategies for drug delivery: Multistage porous silicon microvectors.

Authors:  Alessandro Venuta; Joy Wolfram; Haifa Shen; Mauro Ferrari
Journal:  J Mater Chem B       Date:  2016-11-26       Impact factor: 6.331

Review 7.  CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.

Authors:  Elvira Favoino; Marcella Prete; Andrea Marzullo; Enrico Millo; Yehuda Shoenfeld; Federico Perosa
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

Review 8.  Therapeutic potential of HIV-1 entry inhibitor peptidomimetics.

Authors:  Nneka Pu Korie; Kwesi Z Tandoh; Samuel K Kwofie; Osbourne Quaye
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-17

9.  A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization.

Authors:  Shanthi P Kanthala; Yong-Yu Liu; Sitanshu Singh; Rushikesh Sable; Sandeep Pallerla; Seetharama D Jois
Journal:  Oncotarget       Date:  2017-07-05

Review 10.  Heterocycles as a Peptidomimetic Scaffold: Solid-Phase Synthesis Strategies.

Authors:  Aizhan Abdildinova; Mark J Kurth; Young-Dae Gong
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.